Apollo Endosurgery Inc (NASDAQ: APEN) announced the marketing authorization of the Apollo ESG, Apollo ESG Sx, Apollo REVISE, and Apollo REVISE Sx Systems through the FDA De Novo Classification ...

Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the second ...

NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) — Apollo Global Management, Inc. (NYSE: APO) (together with its consolidated subsidiaries, “Apollo”) today published its 13 th annual ESG report, Driving a ...

Read more: BlackRock’s Hildebrand Predicts ‘Vast Reallocation’ Into ESG Apollo has expanded its ESG team in the past year and developed a proprietary rating system for its credit platform. The New ...

Contacts Apollo Endosurgery, Inc. Media Contact: Jen Cook, 512-279-5158 [email protected] or Investor Contacts: Stefanie Cavanaugh, 512-279-5100 Chief Financial Officer investor-relations ...

AUSTIN, TX / ACCESSWIRE / August 31, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, ...

Apollo has submitted a De Novo classification request to the U.S. Food and Drug Administration seeking 510 (k) classification and clearance for the Apollo ESG TM and Apollo REVISE TM devices. More ...